Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PhD Position in Stem Cells in Lung Regeneration and Repair ...
akademischestellen.com › phd-position-in-stem
The Lung Research laboratory is a located at Murtenstrasse 50 and later in the new building of the Department of Biomedical research (www.dbmr.unibe.ch), with state of art facilities. You will be working with a motivated team with a very social and friendly environment.
PhD student position: Stem cells in lung regeneration and repair
Applications are invited for a PhD student position in the Lung Research Laboratory at the Department of Biomedical Research, University of Bern and the Department of Pulmonary Medicine, University Hospital Bern, Switzerland (Head: Prof. Thomas Geiser).
Please send your CV with a brief letter explaining your previous research activities and 3 references to:
PD Amiq Gazdhar, MD-PhD
Senior Scientist and Group Leader
amiq.gazdhar@dbmr.unibe.ch
phone +41 31 632 76 34
https://akademischestellen.com/phd-position-in-stem-cells-in-lung-regeneration-and-repair,i5662.html
Exploiting the Network for Future Directions
The SCRM Steering Committee (supported by a Scientific
Advisory and a Strategic Board) has recently been joined
by two new young investigators (Prof. Benjamin
Gantenbein and Dr. Amiq Gazdhar) which are proactive
in establishing a curriculum for Stem Cells and
Regenerative Medicine together with Prof. Volker
Enzmann and the GCB. In extension of its active
involvement in designing the GMP unit at Sitem-Insel,
the SCRM Platform is also a driving force behind the
foundation of a private/public Swiss-wide Cell Therapy
Platform connecting Bern, under the umbrella of the
national thematic networks and Biotechnet Switzerland,
with University Centers for Cell Therapies in Geneva,
Lausanne, Lugano, Basel and Zürich.
Platform for Stem Cells and Regenerative
Medicine
Prof. Eliane J Müller & Prof. Volker Enzmann
The CNB and the Platform for Stem Cells and
Regenerative Medicine (SCRM) have partnered to link
their respective networks and pursue common interests.
The SCRM Platform is a research cluster of the
Department of BioMedical Research (DBMR) at the
University of Bern founded in 2015
(www.stemcellsbern.ch). It comprises 37 member
groups affiliated with the Medical Faculty and Inselspital
University Hospital, the Vetsuisse and Phil.-nat. Faculty.
https://www.neuroscience.unibe.ch/unibe/portal/microsites/micro_clinicneuro/content/e90710/e402684/e641811/e641815/CNBNewsletter17_10.pdf
STEM CELL LUNCH SEMINAR – PROGRAM 2021
Responsible : Dr. med. Amiq Gazdhar and Rene Aeberhard
http://www.stemcellsbern.ch/wb/media/PDFs/Lunchmeeting%202021%20FINAl.pdf
You think wyss and Bertarelli would be interested!!
Research unit INNOSUISSE
Project number 8082.1;5 LSPP-LS
Project title Development of an RSV vaccine based on recombinant RSV-F expressed in mammalian cells and formulated in influenza virosomes
Basic data Texts Participants
Participants
Research organisation: Innosuisse
Swiss Innovation Agency
Einsteinstrasse 2
CH-3003 Bern
+41 58 461 61 61 (Call Center)
info@innosuisse.ch
www.innosuisse.ch/
Contact person
Prof. Dr.
Florian Wurm
EPFL
CH J2 506 (Bâtiment CH), Station 6
CH-1015 Lausanne
021 693 61 41
florian.wurm@epfl.ch
https://www.aramis.admin.ch/Beteiligte/?ProjectID=22008
Characterizing the respiratory tract immune response after nasal COVID-19 vaccination
Participants
Research organisation: Innosuisse
Swiss Innovation Agency
Einsteinstrasse 2
CH-3003 Bern
+41 58 461 61 61 (Call Center)
info@innosuisse.ch
www.innosuisse.ch/
Contact person
Amiq Gazdhar
Insel Gruppe AG
Murtenstrasse 50
CH-3008 Bern
+41 31 632 76 34
amiq.gazdhar@dbmr.unibe.ch
Main Implementation Partner
Doktor
Silvain Fleury
Mymetics SA
Route de la Corniche 4
CH-1066 Epalinges
+41 21 653 24 72
sylvain.fleury@mymetics.com
https://www.aramis.admin.ch/Beteiligte/?ProjectID=47917
ARAMIS PROJECT VIROSOMES
https://www.aramis.admin.ch/Projektsuche/
Covid-19 research project registry
This project database offers an overview of research on Covid-19 funded by the SNSF, by Innosuisse, or within the European Framework programme Horizon 2020 with Swiss participation.
Characterizing the respiratory tract immune response after nasal COVID-19 vaccination
Applicants Amiq Gazdhar
Project partners, other involved researchers
Funding Innosuisse
Institute Insel Gruppe AG, Bern
Research Institution University of Berne - BE
Start / End 30.11.2020 - 29.11.2021
Granted amount (EUR for EU, else CHF) 418,017
State ongoing
Funding scheme Projektförderung
Project ID 49697.1 IP-LS
Keywords
Main discipline
URL https://www.aramis.admin.ch/Projektsuche/
Scientific Abstract
Characterizing the nasal COVID-19 vaccine-induced immune responses in the blood, nose and lungs of young and mid-age adult rats to confirm the virosomes-RBD vaccine safety, tolerate, while eliciting protective respiratory immunity to block nasal infection and virus spreading to the lungs and brain.
https://data.snf.ch/covid-19/innosuisse/49697.1%20IP-LS
using advanced microfluidic chip technology
ABSTRACT: Our understanding of mesenchymal cell subsets and their function in human lung affected by aging and in certain disease settings remains poorly described. We use a combination of flow cytometry, prospective cell-sorting strategies, confocal imaging, and modeling of microvessel formation using advanced microfluidic chip technology to characterize mesenchymal cell subtypes in human postnatal and adult lung. Tissue was obtained from patients undergoing elective surgery for congenital pulmonary airway malformations (CPAM) and other airway abnormalities including chronic obstructive pulmonary disease (COPD). In microscopically normal postnatal human lung, there was a fivefold higher mesenchymal compared with epithelial (EpCAM
https://www.expertscape.com/ar/stem+cells/a/Amacker%2C+Mario
Microfluidic Chip Simplifies COVID-19 Testing, Delivers Results on a Phone in 55 Minutes or Less
TOPICS:COVID-19Mechanical Engineering Nanotechnology Public Health Rice University
By RICE UNIVERSITY MARCH 2, 2021
https://scitechdaily.com/microfluidic-chip-simplifies-covid-19-testing-delivers-results-on-a-phone-in-55-minutes-or-less/
Microfluidic devices for the detection of viruses: aspects of ...
royalsocietypublishing.org › doi › 10
Nov 04, 2020 · Similar approaches to on-chip amplification of genetic fragments were tested for the detection of avian influenza DNA (H7N9) , influenza A (H1N1) , Zika (ZIKV) , dengue (DENV) , MERS (MERS-CoV) , SARS (SARS-CoV) and COVID-19 (SARS-CoV-2) . These different studies show the great potential for microfluidics to replace or supplement benchtop ...
Author: José Alvim Berkenbrock, Rafaela Grecco-Machado, Sven Achenbach
Cited by: 4
https://royalsocietypublishing.org/doi/10.1098/rspa.2020.0398
The researchers recommend that special efforts be put into virosome-based viral vaccine improvements, such as the Transvac 2, a new virosomal vaccine designed against SARS-CoV-2 viruses. Transvac 2 is in phase ?? clinical trials. It is an innovative compound expected to be helpful in the recent viral pandemic.
In this review, the authors addressed important questions on the nature, preparation and popularity of the virosomes, highlighting their significance in the wake of COVID-19.
Journal reference:
Asadi, Khatereh and Ahmad Gholami. (2021) Virosome-based nanovaccines; a promising bioinspiration and biomimetic approach for preventing viral diseases: A review. International Journal of Biological Macromolecules. https://doi.org/10.1016/j.ijbiomac.2021.04.005, https://www.sciencedirect.com/science/article/pii/S0141813021007601
https://aboutcancerservice.com/health-news/could-virosome-based-nanovaccines-be-a-promising-new-approach-to-preventing-viral-diseases-2/
Continue from last post
http://esvc001414.wic005tu.server-web.com/
Norwood Talks about Future in stem cells
https://www.asx.com.au/asxpdf/20090309/pdf/31gh5dqy4v7c74.pdf
CD90+CD146+ identifies a pulmonary mesenchymal cell subtype with both immune modulatory and perivascular-like function in postnatal human lung
Limei Wang,* Patrick Dorn,* Soheila Zeinali, Laurène Froment, Sabina Berezowska, Gregor J. Kocher, Marco P. Alves, Melanie Brügger, Blandina I. O. Esteves, Fabian Blank, Carlos Wotzkow, Selina Steiner, Mario Amacker, Ren-Wang Peng, Thomas M. Marti, Olivier T. Guenat, Peter K. Bode, Ueli Moehrlen, Ralph A. Schmid, and Sean R. R. Hall Show fewer authors
02 APR 2020https://doi.org/10.1152/ajplung.00146.2019
https://journals.physiology.org/doi/full/10.1152/ajplung.00146.2019
CD90+CD146+ identifies a pulmonary mesenchymal cell subtype with both immune modulatory and perivascular-like function in postnatal human lung
https://www.alveolix.com/publications/cd90cd146-identifies-a-pulmonary-mesenchymal-cell-subtype-with-both-immune-modulatory-and-perivascular-like-function-in-postnatal-human-lung/
SEC
www.sec.gov › Archives › edgar
Fruci & Associates II, PLLC . We have served as the Company’s auditor since 2016 and resigned on April 12, 2019 . Spokane, WA July 25, 2018 . 12 . CANNABIS SUISSE CORP. (Formerly Geant Corp.) CONSOLIDATED BALANCE SHEETS
https://www.sec.gov/Archives/edgar/data/1680132/000168013219000035/cannabissuissecorp10kmay2019.htm
CBD of Denver Provides Update on Its US Audit
finance.yahoo.com › news › cbd-denver-provides-us
Jun 08, 2021 · As announced earlier this year, CBD of Denver engaged Fruci Associates to fulfil the US audit requirement for the Company to become a fully reporting company according to SEC guidelines. Due to ...
https://finance.yahoo.com/news/cbd-denver-provides-us-audit-115400850.html
Author: Newsfile Corp.
CBD of Denver Announces Successful Completion of Swiss Audit ...
www.marketwatch.com › press-release › cbd-of-denver
Apr 23, 2021 · CBD of Denver has engaged Urs Rindlisbacher, a Swiss chartered accountant and audit expert with Auditrium AG and PCAOB registered auditor Kory Kolterman at Fruci Associates II, to perform an audit ...
https://www.marketwatch.com/press-release/cbd-of-denver-announces-successful-completion-of-swiss-audit-2021-04-23
In November 2014, Kory became an audit partner. Since then, the majority of his time is spent focused on auditing public companies and compliance with interim and annual reporting requirements for SEC registrants.
https://www.fruci.com/kory-kolterman
I wonder why they pick them out of Spokane, WA. Why not another firm out of Seattle, WA. Has to be something why MYMX did this out of Spokane, WA Interesting.
Alex Yashchuk - Tax Preparer - Fruci & Associates, PS | LinkedIn
www.linkedin.com › in › alex-yashchuk-07205a122
Tax Preparer at Fruci & Associates, PS Spokane, Washington Area 113 connections. Join to Connect Fruci & Associates, PS ... R&D Project Manager – PLVision Ukraine. Alexander Yashchuk.
Location: Spokane, Washington
Rachel Harris - Staff Auditor - Fruci & Associates, PS | LinkedIn
www.linkedin.com › in › rachel-harris-888336a3
Fruci & Associates, PS. Apr 2015 – Present5 years 5 months. Spokane, WA. - Perform audits of corporations adhering to standards and regulations prescribed by the PCAOB. - Plans financial audits ...
Location: Spokane, Washington
Thus, virosomes increase the tumor-specific antibody and T cell responses (175, 176), as has been observed in phase I clinical trial on metastatic breast cancer patients.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=164043582
CK-CARE - helmholtz-muenchen.de
www.helmholtz-muenchen.de › en › institute-of
CK-CARE, Christine Kühne – Center for Allergy Research and Education, was set up by the Kühne Stiftung in summer 2009. At the beginning, the locations of the internationally strongly networked initiative were Davos, Zurich (both: Switzerland), and Munich (Germany).
CK-CARE, Christine Kühne - Center for Allergy Research and Education, Davos
CK-CARE, Christine Kühne – Center for Allergy Research and Education, was set up by the Kühne Stiftung in summer 2009. At the beginning, the locations of the internationally strongly networked initiative were Davos, Zurich (both: Switzerland), and Munich (Germany). Augsburg, Bonn (both: Germany), and St Gallen (Switzerland) were established as further locations in 2014. The intitiative´s main focus is on allergy research as well as on the education of physicians, researchers, and scientists, but also of specialist staff of clinics and medical offices.
Professor Claudia Traidl-Hoffmann is board member in the CK-CARE executive board, and she is head of the research assignment Workpackage 1 (WP1; see below). Since its foundation, CK-CARE has been annually organizing the Allergy Forum, Davos, Switzerland (one among many other projects of CK-CARE). At this forum, young scientists plus long established groups of well-experienced scientists from all over the world meet for an exchange of knowledge and for the planning of new projects. The IEM participates in these conferences on a regular basis and is proud to have CK-CARE as a reliable partner by its side.
The close relationship between the IEM and CK-CARE is based on a perennial and successful cooperation unit. Both partners continue to exchange information on a regular basis, to increase their international alignment and stay in close contact with each other through their agreement on a common goal achievement - the therapy and eventually the prevention of allergies.
Information about Workpackage 1
Professor Claudia Traidl-Hoffmann is in charge of Workpackage 1 (WP1) at CK-CARE. The main locations for the corresponding research units are Munich and Augsburg (both: Germany).
Workpackage 1 researches about “The influence of the environment on atopic diseases". The chief aim hereby is to identify and to analyze those environmental factors which cause allergies and which exert an influence on the progression of this disease. Especially the study of pollen and spores is of great importance, and is first of all conducted under greenhouse conditions in climate chambers but also directly in the nature.
It is only this intensive research activity which makes it possible to develop strategies for the early treatment and for a complete prevention of allergies in the future. For this purpose, CK-CARE provides an extraordinary support. The combination with the other Workpackages (2-5) creates synergetic effects which enable us to introduce the most recent research results directly into the respective teaching program.
https://www.helmholtz-muenchen.de/en/institute-of-environmental-medicine/ck-care/index.html
https://onlinelibrary.wiley.com/doi/full/10.1111/all.14077
You could be on to something there my Friend!!
Prof. Dr. Gregor Zünd has been CEO and President of the Hospital Executive Board of the Zurich University Hospital since 2016. Before his appointment, he was Director of Research and Education and in this function already a member of the Executive Board of the Zurich University Hospital and Managing Director of the Centre for Clinical Research. Prof. Zünd is a specialist in cardiac and thoracic heart surgery. He completed further trainings at the Zurich University Hospital. In addition, he spent several years at the Texas Medical Center in Houston and at the Harvard Medical School in Boston. Prof. Zünd is member of the Medical Faculty at the University of Zürich.
Lukas Fierz is someone who always speaks up, who represents his point of view, who cannot be bent. "That's why my removal from parliament was logical," he says today. Sunday, 23.10.2016, 09:58 hrs
Bern Fribourg Valais
-
"I couldn't write for 30 years because I was so angry"
The publicist, former National Councillor, neurologist and cellist Lukas Fierz (75) had to write a book with 22 stories. Stories from his work as a doctor and reviewer, which must be made public, he says. A book against screaming injustice.
https://www.srf.ch/news/regional/bern-freiburg-wallis/30-jahre-konnte-ich-nicht-schreiben-weil-ich-so-wuetend-war
If you have something show it and share it!! WH held this up for a long time, Do not go there my friend! You have something to share, I'm calling you out to share what you got!
I think this stock is only good for flipping now!!!
Hey! Puppet Masters MYMX belongs to Stinky pinky land not otc! The way you run this company!!
BIOPOLE NOT MUCH THERE! https://www.dlf.pt/png/big/33/331729_flag-pole-png.png
Yep! It will go down!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Where's our Burgers Puppet Masters ( They control you Mr. K)
https://media.istockphoto.com/vectors/political-leader-or-a-businessman-who-is-guided-by-someone-else-vector-id1004029280?k=6&m=1004029280&s=612x612&w=0&h=eVe8iRnS-44znrrtoTc6oK5hssaHF8eDaz7tfW4lxmI=
https://www.pngkey.com/png/detail/427-4273237_hamburger-clipart-transparent-food-pencil-and-in-color.png
Transplant Center
Lung transplantation
Department of Pneumology
Department of Pneumology
Prof. Th. Geiser (
TransplantBoard) Director and Chief Physician
University Hospital of
Pneumology Inselspital
3010 Bern T +41 31
632 27 68E-Mail
http://www.transplantnet.ch/de/organtransplantation/lunge/kontaktlunge/
The common cold virus "Respiratory Syncytial Virus" (RSV) can cause serious respiratory infections. Vaccination of newborn children and elderly people with reduced immune systems could reduce the risk of infection and complications. According to research by Muhammad Shafique Msc. (Pakistan, 1974) is a nasal spray suitable for the administration of a new type of vaccine against RSV. On March 13, 2013, he obtained his doctorate from the University of Groningen, with prof.dr. J.C. Wilschut on his thesis 'Development of a mucosal vaccine against Respiratory Syncytial Virus infection'. The new vaccine consists of virosomes, a virus coat without the genetic material of the virus. Substances have been added to the virosomes that should cause a stronger immune response in the body. In an animal model, this vaccine provoked an immune response in the blood and respiratory tract and appeared to provide protection against infection. Administration via a nasal spray proved to be suitable for both young laboratory animals and animals with an outdated immune system. Shafique studied Biotechnology at the Quaid-I-Azam University in Islamabad. He conducted his PhD research at the Department of Medical Microbiology, Section Molecular Virology of the University Medical Center Groningen (UMCG) within the framework of the GUIDE Research Institute. eDI tOrIaL NEWs[advertisement]VaccineVaccine is the pre-eminent journal for those interested in vaccines and vaccination. Submissions to the following categories are welcomed:• Human Vaccines – Infectious Diseases (bacterial, viral and other)• Human Vaccines – Non Infectious Diseases (cancer, addiction, auto-immunity and other) • Veterinary Vaccines• Delivery systems / Vectors / Adjuvants• Immunology / Animal models• Regulatory / Societal / Legislation Aspects
Busy today my friend!!
2020 Program Highlights - IPVC 2021 (34th International ...
ipvconference.org › 2020-program-highlights
Rafi Ahmed, USA (Emory Vaccine Center, Director) ... Dr. Maurice Hilleman led Merck MSD’s Department of Virus and Cell Biology from 1956 to 1984. Of the fourteen ...
https://ipvconference.org/2020-program-highlights/#1595237428077-66302d8f-16b2
Scientific Advisory Board | INOVIO Pharmaceuticals
www.inovio.com › about-inovio › scientific-advisory
Rafi Ahmed, Ph.D. Director, Emory Vaccine Center, Emory University School of Medicine Rafi Ahmed, Ph.D. Director, Emory Vaccine Center, Emory University School of Medicine Anthony Ford-Hutchinson, Ph.D. Former Senior Vice President, Vaccines R&D, Merck
https://www.inovio.com/about-inovio/scientific-advisory-board/
2019 Award for Distinguished Research in the Biomedical ...
www.aamc.org › distinguished-research › 2019-ahmed
Jun 04, 2021 · Dr. Ahmed’s laboratory was also the first to demonstrate T-cell exhaustion due to chronic viral exposure and show that this dysfunction was due to the inhibitory receptor programmed cell death -1 (PD-1). In 2006, Dr. Ahmed published findings in Nature demonstrating that T-cell function could be restored via antibodies that block PD-1.
https://www.aamc.org/what-we-do/aamc-awards/distinguished-research/2019-ahmed
The Division of Immunology and Allergy
www.chuv.ch › fileadmin › sites
Professeur Giuseppe PANTALEO Médecin-Chef de Service Professeur François SPERTINI Médecin-Chef Secrétariat général Tél.: +41-21-314.07.90 ial.info@chuv.ch www.immunologyresearch.ch The Division of Immunology and Allergy is looking for its new: Postdoctoral position Projects:
https://www.chuv.ch/fileadmin/sites/ial/documents/ial-annonce-postdoc_07.06.2012.pdf
https://www.chuv.ch/fr/ial/ial-home/le-service-en-bref/short-cv/
Giuseppe Pantaleo
https://www.eurovacc.org/about/board-of-directors/
Leadership Group | Emory University | Atlanta GA
idcrc.org › about › leadership-group
Robert L Atmar, MD (Baylor College of Medicine) COU Co-Director, Expert Working Groups Liaison . ratmar@bcm.edu ... Julie McElrath, MD, PhD (University of Washington)
https://idcrc.org/about/leadership-group/index.html
Remember Carl R Alving:
Carl R Alving | PubFacts
www.pubfacts.com › author › Carl+R+Alving
Carl R Alving Toggle navigation ... 2021 Mar 18;9(3). Epub 2021 Mar 18. ... The licensed virosome vaccines to influenza and hepatitis A will be replaced with virosome ...
https://www.pubfacts.com/author/Carl+R+Alving
Hoping to get the op to fly it, Friend of mine has a business flying executives to California. He has two King Air B200 Double prop turbo that I love to fly, my favorite. He just bought this one, was a demo!!
Might get a op to fly this!! :)
https://www.hondajet.com/?utm_source=VDX&utm_medium=banner&utm_campaign=EliteS
Prof. Dr. Anke Huckriede Department of Medical
Microbiology University Medical Center Groningen
Research Interests:
My research interests center on the development of vaccines against respiratory viruses, in particular influenza. Integrating knowledge of the relevant correlates of immune protection with recent insights in immunology, in particular mechanisms of innate immunology, my group attempts to take a rational approach towards the design of novel influenza vaccine modalities and formulations. Our research activities can be divided into three major research lines. Using systems immunology techniques we try to find new leads for the development of improved vaccines. Among others, we have set up an in vitro vaccine evaluation system based on human PBMCs which can aid in the selection of promising vaccine candidates. For the generation of universal influenza vaccines we re-evaluate old and design new vaccine formulations containing conserved virus antigens to evoke broadly reactive humoral and cellular immune responses. These activities we pursue in the context of the FP7 Project 'UNISEC' of which I am co-coordinator. In collaboration with my colleagues Professor H.W. Frijlink and Dr. W.L.J. Hinrichs from the Department of Pharmacy, University of Groningen, my group works on stabilization of influenza vaccines to increase vaccine shelf life and to enable vaccine administration via new, effective and patient-friendly ways like inhalation and sublingual delivery.
https://www.medizin.uni-muenster.de/fluresearchnet/members/prof-dr-anke-huckriede.html#top
FP7 Project 'UNISEC'
https://cordis.europa.eu/project/id/602012/reporting